cilgavimab and tixagevimab (Evusheld) (n=3460) vs. placebo (n=1737)
randomized controlled trial
low risk of bias
tixagevimab (AZD8895) and cilgavimab (AZD1061)
single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of 300 mg of AZD7442
placebo
COVID-19 prophylaxis (excluding children)
double-blind
87 sites in the US, UK, Spain, France and Belgium
*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.* preliminary results reported in a press release https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html